LFWD · Insider Trading
Lifeward Ltd. Ordinary Shares
Every open-market purchase and sale reported by LFWD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Haggai Zamir | Director | A | +6,711 | — |
| 2026-08-28 | Yonason Greenwald | Director | A | +6,711 | — |
| 2026-08-24 | Avraham Gabay | Director | A | +13,643 | — |
| 2026-05-20 | Keith Dale Rose | Chief Medical Officer | A | +15,000 | — |
| 2026-04-13 | William Mark Sigsbee | Director | A | +11,485 | — |
| 2026-04-13 | Moshe H Rozenbaum | Director | A | +11,485 | — |
| 2026-03-27 | William Mark Grant | President & CEO | A | +172,698 deriv. | — |
| 2026-03-27 | Yehuda Reznick | Director | A | +7,657 | — |
| 2026-03-27 | Miriam Kidron | Director | A | +7,657 | — |
| 2026-03-27 | Nadav Kidron | Director | A | +7,657 | — |
| 2026-03-27 | Almog Adar | Chief Financial Officer | A | +39,934 deriv. | — |
| 2025-12-12 | Jeannine Lynch | VP of Market Access & Strategy | A | +50,000 | — |
| 2025-09-04 | Jeannine Lynch | VP of Market Access & Strategy | Sell | −1,591 | −$1.02K |
| 2025-08-13 | Almog Adar | Chief Financial Officer | A | +225,000 deriv. | — |
| 2025-08-07 | Hadar Levy | Director | A | +35,920 | — |
| 2025-08-07 | John William Poduska Sr | Director | A | +35,920 | — |
| 2025-08-07 | Randel Richner | Director | A | +35,920 | — |
| 2025-08-07 | Robert J. Marshall Jr. | Director | A | +35,920 | — |
| 2025-08-07 | Joseph E Turk Jr | Director | A | +71,839 | — |
| 2025-08-07 | Michael Swinford | Director | A | +35,920 | — |
| 2025-06-04 | William Mark Grant | President & Co-CEO | A | +400,000 deriv. | — |
| 2025-05-22 | Lawrence J Jasinski | Chief Executive Officer | Sell | −1,909 | −$2.41K |
| 2025-01-08 | Lind Global Fund II LP | 10%+ Owner | Sell | −573,110 | −$1.66M |
| 2024-12-17 | Randel Richner | Director | Sell | −4,285 | −$7.21K |
| 2024-12-17 | Joseph E Turk Jr | Director | Buy | +6,000 | +$10.14K |
| 2024-11-27 | Michael Swinford | Director | Buy | +21,622 | +$43.86K |
| 2024-11-26 | Michael Swinford | Director | Buy | +16,907 | +$30.90K |
| 2024-11-25 | Michael Swinford | Director | Buy | +16,471 | +$30.23K |
| 2024-09-16 | Lawrence J Jasinski | Chief Executive Officer | Sell | −2,672 | −$8.70K |
| 2024-09-04 | Jeannine Lynch | VP of Market Access & Strategy | Sell | −1,625 | −$5.36K |
| 2024-08-06 | Jeannine Lynch | VP of Market Access & Strategy | Sell | −1,783 | −$6.85K |
| 2024-08-06 | Lawrence J Jasinski | Chief Executive Officer | Sell | −2,665 | −$10.23K |
| 2024-07-02 | Jeannine Lynch | VP of Market Access & Strategy | Sell | −1,834 | −$7.02K |
| 2024-06-21 | Lawrence J Jasinski | Chief Executive Officer | Sell | −3,466 | −$14.62K |
| 2024-05-28 | Michael A Lawless | Chief Financial Officer | Buy | +2,000 | +$9.94K |
| 2024-05-24 | Joseph E Turk Jr | Director | Buy | +8,000 | +$40.08K |
| 2024-05-23 | Lawrence J Jasinski | Chief Executive Officer | Sell | −1,620 | −$7.95K |
| 2024-04-22 | Michael Swinford | Director | A | +10,040 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Lind Global Fund II LP | 10%+ Owner | 71,500 | $415.42K |
| Keith Dale Rose | Chief Medical Officer | 17,083 | $99.25K |
| Avraham Gabay | Director | 13,643 | $79.27K |
| Jeannine Lynch | VP of Market Access & Strategy | 11,845 | $68.82K |
| William Mark Sigsbee | Director | 11,485 | $66.73K |
| Moshe H Rozenbaum | Director | 11,485 | $66.73K |
| Joseph E Turk Jr | Director | 8,748 | $50.83K |
| Michael Swinford | Director | 8,413 | $48.88K |
| Lawrence J Jasinski | Chief Executive Officer | 8,405 | $48.83K |
| Miriam Kidron | Director | 7,657 | $44.49K |
| Yehuda Reznick | Director | 7,657 | $44.49K |
| Nadav Kidron | Director | 7,657 | $44.49K |
| Yonason Greenwald | Director | 6,711 | $38.99K |
| Haggai Zamir | Director | 6,711 | $38.99K |
| Randel Richner | Director | 4,791 | $27.84K |
| John William Poduska Sr | Director | 4,663 | $27.09K |
| Hadar Levy | Director | 4,298 | $24.97K |
| Robert J. Marshall Jr. | Director | 2,993 | $17.39K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LFWD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.